Individuals with CD who received treatment with biologics preoperatively have improved endoscopic outcomes when switching to a different biologic postoperatively.

A new tool can help physicians determine which patients with localized pancreatic neuroendocrine tumors (PanNETs) have an ...

James Stewart puts on his rollerblades to get ready to do the trail in Rabb Park on his day off. He continues to be able to ...

The new risk score could help better manage the follow-up care for patients who've had pancreatic tumors surgically removed, and whose cancers have not spread to their lymph nodes, researchers wrote ...

A risk score based on four factors — male sex, tumor size, World Health Organization (WHO) grade, and lymphovascular invasion — predicts recurrence in patients with node-negative pancreatic ...

The score could help better manage the follow-up care for patients who’ve had pancreatic tumors surgically removed, and whose cancers have not spread to their lymph nodes, researchers wrote Dec. 17 in ...

The 13-point risk score can help doctors more closely monitor patients at higher risk About 10% of patients suffer a cancer recurrence, most often in their liver FRIDAY, Dec. 19, 2025 (HealthDay News) ...

Young women with breast cancer experience higher recurrence risks and often present with advanced disease due to symptomatic detection rather than standard screening. Molecular studies show young ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring ...

—For certain older patients with low-genomic-risk, early-stage breast cancer, the findings from a new study suggest that some of them may be able to forgo either radiotherapy or endocrine therapy ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...